Status:
COMPLETED
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
Lead Sponsor:
Spur Therapeutics
Conditions:
Fabry Disease
Lysosomal Storage Diseases
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Fabry disease is a rare, X-linked inborn error of glycosphingolipid metabolism caused by an abnormal gene encoding the α-galactosidase A (αGLA) enzyme. The αGLA enzyme is ubiquitously expressed throug...
Eligibility Criteria
Inclusion
- Subjects who have previously received FLT190
- Provision of full informed consent and able to comply with all requirements of the study including long-term follow-up for 60 months (5 years) post-treatment.
Exclusion
- N/A
Key Trial Info
Start Date :
September 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 28 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04455230
Start Date
September 8 2020
End Date
September 28 2023
Last Update
December 7 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - Universitätsmedizin Berlin
Berlin, Germany
2
Royal Free London
London, United Kingdom